Developer docs
API playgroundTry for free, no card

Search company profiles

Satsuma Pharmaceuticals

Full company profile

uuid0003dkj

Namestring
Satsuma Pharmaceuticals
Legal namestring
Satsuma Pharmaceuticals, Inc.
Websiteurl
satsumarx.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Satsuma Pharmaceuticals is a biopharmaceutical company that develops and is preparing to commercialize therapeutics for the acute treatment of migraine. Founded in 2016 and headquartered in Durham, North Carolina (Research Triangle Park), the company was spun out of Japanese CRO Shin Nippon Biomedical Laboratories (SNBL) in January 2017 with a $12 million Series A, IPO'd on NASDAQ under ticker STSA in September 2019, and was taken private by parent SNBL in June 2023 after a tender offer. As of the most recent data, Satsuma continues active operations as a wholly-owned subsidiary of SNBL.

Its core asset is Atzumi (formerly STS101), an FDA-approved (April 30, 2025) dihydroergotamine nasal powder indicated for the acute treatment of migraine with or without aura in adults — the first and only DHE nasal powder on the market. The product is built on Satsuma's proprietary SMART (Simple MucoAdhesive Release Technology) platform, which pairs a dry-powder DHE formulation with a mucoadhesive drug carrier and engineered drug particle technology, delivered via a single-use, pre-filled nasal device. Phase 3 data (SUMMIT and ASCEND, totaling 1,500+ subjects and 10,000+ migraine attacks) demonstrated mean DHE plasma concentrations of 2.0 ng/mL within approximately 15-20 minutes, sustained levels above 1.0 ng/mL for 2 hours, freedom from pain and most bothersome symptoms at 2 hours, and durability of benefit through 48 hours.

The business model is prescription pharmaceutical sales of Atzumi through US pharmacy distribution channels, with go-to-market targeting neurologists and UCNS-certified headache specialists who treat acute migraine patients, particularly those who have failed oral therapies or cannot tolerate existing DHE formulations (Migranal liquid nasal spray, injectable DHE). Satsuma has appointed a Chief Commercial Officer, publishes in peer-reviewed headache journals, and presents at the American Headache Society Annual Scientific Meeting, but operates with only 1-10 employees and has not yet commenced commercial sales; no revenue is disclosed. Total equity raised across the Series A ($12M, 2017), Series B ($62M, April 2019), IPO (~$82.5–90.8M gross, September 2019), and a March 2021 follow-on ($80M) exceeded $235M.

Short descriptiontext

Satsuma Pharmaceuticals is a biopharmaceutical company that develops and is preparing to commercialize Atzumi, an FDA-approved dihydroergotamine nasal powder for the acute treatment of migraine in adults, using its proprietary SMART mucoadhesive dry-powder nasal delivery platform. It operates as a privately held subsidiary of Japan's SNBL.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
acute migraine treatment, nasal drug delivery, dihydroergotamine therapy, drug-device combinations, migraine therapeutics
Industry2 codes
PRIMARYHLAKAIAE
Headache & Migraine Medicine
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Acute Migraine Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales (Atzumi)
TypeOne Time License
Description

Satsuma's FDA-approved product Atzumi (dihydroergotamine nasal powder) for acute migraine treatment. The company is preparing for commercial launch in the United States. Product is not yet commercially available as of the available data.

investors.satsumarx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Satsuma Pharmaceuticals develops and commercializes a novel therapeutic product for the acute treatment of migraine with or without aura in adults. Its FDA-approved product Atzumi (dihydroergotamine nasal powder, formerly STS101) is the first and only DHE nasal powder for acute migraine, combining a proprietary dry-powder formulation with an easy-to-use, single-use nasal delivery device built on the SMART (Simple MucoAdhesive Release Technology) platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Rapid pain relief: freedom from pain at 2 hours post-administration in Phase 3 studies
+3 more records
Product overview1 text field

Satsuma Pharmaceuticals is a biopharmaceutical company with one FDA-approved product and a proprietary drug delivery technology platform. The company's flagship product is Atzumi™ (formerly known as STS101), a dihydroergotamine nasal powder for the acute treatment of migraine. This product leverages the SMART™ (Simple MucoAdhesive Release Technology) Platform, which combines a proprietary dry-powder formulation with an easy-to-use nasal delivery device. The technology is designed to overcome limitations of existing DHE products by providing better stability, adherence to nasal mucosa, and resistance to dripping compared to liquid formulations.

Product and service1 record
1Atzumi™ (dihydroergotamine nasal powder)
CategoryAcute Migraine Therapeutics
Description

FDA-approved prescription drug-device combination product delivering dihydroergotamine as a dry-powder nasal formulation for the acute treatment of migraine with or without aura in adults. It is designed to provide rapid, sustained relief with a single, self-administered dose using a pre-filled, single-use nasal device.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Markets Ubrelvy (ubrogepant), an oral CGRP antagonist for acute migraine, providing a direct broad-incumbent comparable on prescriber audience, payer dynamics, and acute-migraine commercial strategy.

TypeDirect peer
Description

Developer of Trudhesa, a DHE mesylate nasal spray approved for acute migraine — the closest direct competitor to Atzumi in the non-oral DHE acute-migraine category and head-to-head on the same prescribers (neurologists/headache specialists).

TypeDirect peer
Description

Commercial-stage CNS company with acute migraine and headache adjacencies — comparable as a focused neurology therapeutics commercializer targeting prescribers of acute migraine products.

TypeBroad incumbent
Description

Through its acquisition of Biohaven, Pfizer markets Nurtec ODT, a leading oral CGRP antagonist for acute migraine — the dominant oral alternative that Atzumi must compete against or complement.

TypeDirect peer
Description

Specialty CNS pharmaceutical company with active migraine therapeutic programs, providing a comparable small-cap neurology-focused drug development and commercialization profile to Satsuma.

TypeBroad incumbent
Description

Markets Migranal (DHE liquid nasal spray) for acute migraine, the legacy product Atzumi is being positioned against, and a broad incumbent in migraine and CNS therapeutics.

TypeBroad incumbent
Description

Markets Vyepti (eptinezumab) and acquired Alder Biopharmaceuticals; relevant as a broad migraine incumbent with established headache-specialist sales coverage comparable to Satsuma's target audience.

TypeBroad incumbent
Description

Commercializes Reyvow (lasmiditan) and Emgality for migraine, representing the large-pharma CGRP-era standard of care that defines the competitive backdrop for Atzumi's launch.

TypeEmerging player
Description

Specialty pharma commercializing pain and CNS therapeutics with a similar small/mid-cap US sales force profile; relevant as a model for how a focused company can capture share in a neurologically-prescribed category.

TypeOthers
Description

Satsuma's parent company and a Japan-listed translational CRO with proprietary intranasal drug-delivery technology — comparable as the originator of the SMART platform and the strategic counterparty that took Satsuma private.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Satsuma Pharmaceuticals

Acute Migraine Therapeuticssatsumarx.com

Satsuma Pharmaceuticals is a biopharmaceutical company that develops and is preparing to commercialize Atzumi, an FDA-approved dihydroergotamine nasal powder for the acute treatment of migraine in adults, using its proprietary SMART mucoadhesive dry-powder nasal delivery platform. It operates as a privately held subsidiary of Japan's SNBL.

What Satsuma Pharmaceuticals does

Satsuma Pharmaceuticals is a biopharmaceutical company that develops and is preparing to commercialize therapeutics for the acute treatment of migraine. Founded in 2016 and headquartered in Durham, North Carolina (Research Triangle Park), the company was spun out of Japanese CRO Shin Nippon Biomedical Laboratories (SNBL) in January 2017 with a $12 million Series A, IPO'd on NASDAQ under ticker STSA in September 2019, and was taken private by parent SNBL in June 2023 after a tender offer. As of the most recent data, Satsuma continues active operations as a wholly-owned subsidiary of SNBL.

Its core asset is Atzumi (formerly STS101), an FDA-approved (April 30, 2025) dihydroergotamine nasal powder indicated for the acute treatment of migraine with or without aura in adults — the first and only DHE nasal powder on the market. The product is built on Satsuma's proprietary SMART (Simple MucoAdhesive Release Technology) platform, which pairs a dry-powder DHE formulation with a mucoadhesive drug carrier and engineered drug particle technology, delivered via a single-use, pre-filled nasal device. Phase 3 data (SUMMIT and ASCEND, totaling 1,500+ subjects and 10,000+ migraine attacks) demonstrated mean DHE plasma concentrations of 2.0 ng/mL within approximately 15-20 minutes, sustained levels above 1.0 ng/mL for 2 hours, freedom from pain and most bothersome symptoms at 2 hours, and durability of benefit through 48 hours.

The business model is prescription pharmaceutical sales of Atzumi through US pharmacy distribution channels, with go-to-market targeting neurologists and UCNS-certified headache specialists who treat acute migraine patients, particularly those who have failed oral therapies or cannot tolerate existing DHE formulations (Migranal liquid nasal spray, injectable DHE). Satsuma has appointed a Chief Commercial Officer, publishes in peer-reviewed headache journals, and presents at the American Headache Society Annual Scientific Meeting, but operates with only 1-10 employees and has not yet commenced commercial sales; no revenue is disclosed. Total equity raised across the Series A ($12M, 2017), Series B ($62M, April 2019), IPO (~$82.5–90.8M gross, September 2019), and a March 2021 follow-on ($80M) exceeded $235M.

Satsuma Pharmaceuticals firmographics

Firmographics
Name
Satsuma Pharmaceuticals
Legal name
Satsuma Pharmaceuticals, Inc.
Website
https://satsumarx.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Satsuma Pharmaceuticals is a biopharmaceutical company that develops and is preparing to commercialize Atzumi, an FDA-approved dihydroergotamine nasal powder for the acute treatment of migraine in adults, using its proprietary SMART mucoadhesive dry-powder nasal delivery platform. It operates as a privately held subsidiary of Japan's SNBL.
Ownership category
akta.pro rank

Satsuma Pharmaceuticals industry classification

Industry
Product category
Acute Migraine Therapeutics
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAKAIAE
Headache & Migraine Medicine
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Acute migraine treatment
  • Nasal drug delivery
  • Dihydroergotamine therapy
  • Drug-device combinations
  • Migraine therapeutics

Where Satsuma Pharmaceuticals is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Satsuma Pharmaceuticals business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales (Atzumi): Satsuma's FDA-approved product Atzumi (dihydroergotamine nasal powder) for acute migraine treatment. The company is preparing for commercial launch in the United States. Product is not yet commercially available as of the available data.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Satsuma Pharmaceuticals product offering

Product offering

Core offering

Satsuma Pharmaceuticals develops and commercializes a novel therapeutic product for the acute treatment of migraine with or without aura in adults. Its FDA-approved product Atzumi (dihydroergotamine nasal powder, formerly STS101) is the first and only DHE nasal powder for acute migraine, combining a proprietary dry-powder formulation with an easy-to-use, single-use nasal delivery device built on the SMART (Simple MucoAdhesive Release Technology) platform.

Product overview

Satsuma Pharmaceuticals is a biopharmaceutical company with one FDA-approved product and a proprietary drug delivery technology platform. The company's flagship product is Atzumi™ (formerly known as STS101), a dihydroergotamine nasal powder for the acute treatment of migraine. This product leverages the SMART™ (Simple MucoAdhesive Release Technology) Platform, which combines a proprietary dry-powder formulation with an easy-to-use nasal delivery device. The technology is designed to overcome limitations of existing DHE products by providing better stability, adherence to nasal mucosa, and resistance to dripping compared to liquid formulations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Atzumi™ (dihydroergotamine nasal powder) FDA-approved prescription drug-device combination product delivering dihydroergotamine as a dry-powder nasal formulation for the acute treatment of migraine with or without aura in adults. It is designed to provide rapid, sustained relief with a single, self-administered dose using a pre-filled, single-use nasal device.

Quantifiable outcome

  • Rapid pain relief: freedom from pain at 2 hours post-administration in Phase 3 studies
  • +3 more outcomes

Companies that use Satsuma Pharmaceuticals

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Satsuma Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Satsuma Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves9 records

Expansion highlights5 records

Satsuma Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: Markets Ubrelvy (ubrogepant), an oral CGRP antagonist for acute migraine, providing a direct broad-incumbent comparable on prescriber audience, payer dynamics, and acute-migraine commercial strategy.
  • Pfizer: Through its acquisition of Biohaven, Pfizer markets Nurtec ODT, a leading oral CGRP antagonist for acute migraine — the dominant oral alternative that Atzumi must compete against or complement.
  • Teva Pharmaceutical Industries: Markets Migranal (DHE liquid nasal spray) for acute migraine, the legacy product Atzumi is being positioned against, and a broad incumbent in migraine and CNS therapeutics.
  • Lundbeck: Markets Vyepti (eptinezumab) and acquired Alder Biopharmaceuticals; relevant as a broad migraine incumbent with established headache-specialist sales coverage comparable to Satsuma's target audience.
  • Eli Lilly: Commercializes Reyvow (lasmiditan) and Emgality for migraine, representing the large-pharma CGRP-era standard of care that defines the competitive backdrop for Atzumi's launch.

Direct peers

  • Impel Pharmaceuticals: Developer of Trudhesa, a DHE mesylate nasal spray approved for acute migraine — the closest direct competitor to Atzumi in the non-oral DHE acute-migraine category and head-to-head on the same prescribers (neurologists/headache specialists).
  • Axsome Therapeutics: Commercial-stage CNS company with acute migraine and headache adjacencies — comparable as a focused neurology therapeutics commercializer targeting prescribers of acute migraine products.
  • Tonix Pharmaceuticals: Specialty CNS pharmaceutical company with active migraine therapeutic programs, providing a comparable small-cap neurology-focused drug development and commercialization profile to Satsuma.

Emerging players

  • Collegium Pharmaceutical: Specialty pharma commercializing pain and CNS therapeutics with a similar small/mid-cap US sales force profile; relevant as a model for how a focused company can capture share in a neurologically-prescribed category.

Others

  • Shin Nippon Biomedical Laboratories (SNBL): Satsuma's parent company and a Japan-listed translational CRO with proprietary intranasal drug-delivery technology — comparable as the originator of the SMART platform and the strategic counterparty that took Satsuma private.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Satsuma Pharmaceuticals social profiles

Digital presence

Satsuma Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Satsuma Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles4 records

Satsuma Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Satsuma Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Satsuma Pharmaceuticals

What does Satsuma Pharmaceuticals do?

Satsuma Pharmaceuticals develops and commercializes a novel therapeutic product for the acute treatment of migraine with or without aura in adults. Its FDA-approved product Atzumi (dihydroergotamine nasal powder, formerly STS101) is the first and only DHE nasal powder for acute migraine, combining a proprietary dry-powder formulation with an easy-to-use, single-use nasal delivery device built on the SMART (Simple MucoAdhesive Release Technology) platform.

Is Satsuma Pharmaceuticals a public or private company?

Satsuma Pharmaceuticals is a public company. It is classified as corporate owned and is currently operating.

When was Satsuma Pharmaceuticals founded?

Satsuma Pharmaceuticals was founded in 2016. It employs 11 to 50 people.

Where is Satsuma Pharmaceuticals based?

Satsuma Pharmaceuticals is headquartered in South San Francisco, United States, in the North America region.

How does Satsuma Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Product Sales (Atzumi).

Who are Satsuma Pharmaceuticals's main competitors?

Broad incumbents on record are AbbVie, Pfizer, Teva Pharmaceutical Industries, Lundbeck and Eli Lilly. Direct peers are Impel Pharmaceuticals, Axsome Therapeutics and Tonix Pharmaceuticals. Collegium Pharmaceutical is listed as an emerging player. Shin Nippon Biomedical Laboratories (SNBL) is listed as an others.

Does Satsuma Pharmaceuticals have an API?

No public API is recorded for Satsuma Pharmaceuticals.

What industry is Satsuma Pharmaceuticals in?

Satsuma Pharmaceuticals's product category is Acute Migraine Therapeutics. Its primary akta.pro industry code is HLAKAIAE, Headache & Migraine Medicine, with a secondary code of HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its NAICS code is 325411 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSatsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society’s 68th Annual Scientific MeetingSatsuma Pharmaceuticals announced two clinical program abstracts selected for presentation at the American Headache Society's 68th Annual Scientific Meeting in Orlando, June 4-7, 2026. The abstracts cover pharmacokinetic comparisons and adverse event profiles of its migraine treatments, with posters scheduled for Thursday evening.PR NewswireSatsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in HeadacheSatsuma Pharmaceuticals and its parent company Shin Nippon Biomedical Laboratories announced the publication of 12-month patient impression data from the pivotal Phase 3 ASCEND study for STS101 (Atzumi™), a nasal powder formulation of dihydroergotamine for acute migraine treatment. The study enrolled 482 patients across 54 U.S. sites, with results showing that most participants found STS101 easy to use and reported it worked faster and more consistently than their usual migraine medications, enabling faster return to normal activities. The publication in the journal Headache reinforces the product's potential as a well-tolerated treatment delivering rapid and sustained symptom relief for migraine patients.PR NewswireMigraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsightThe FDA approved ATZUMI and BREKIYA, new migraine treatments, reshaping the market with improved efficacy and convenience. These therapies may capture share from existing CGRP inhibitors, intensifying competition and driving pricing adjustments. The migraine market is forecast to grow from $10.8 billion in 2023 to a larger figure by 2034.BenzingaSatsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying - Aprea Therapeutics (NBenzinga reported notable insider transactions in three penny stocks on NASDAQ: Satsuma Pharmaceuticals saw its 10% owner Shin Nippon Biomedical Laboratories acquire 30.5 million shares for approximately $27.73 million along with Director Ken Takanashi purchasing shares worth $20 million, coinciding with FDA acceptance of the company's 505(b)(2) NDA for STS101, an investigational nasal powder for acute migraine treatment. Erasca's Chairman and CEO Jonathan Lim acquired 100,000 shares for around $275,000 as the company announced it would discontinue its ERAS-007 program. Aprea Therapeutics Director Bernd Seizinger purchased 10,097 shares for approximately $36,960 following the company's posting of a narrower quarterly loss.PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, TESS, NATI, STSAHalper Sadeh LLC, an investor rights law firm, announced investigations into four pending acquisition transactions for potential violations of federal securities laws and breaches of fiduciary duties to shareholders. The transactions under review are Heska Corporation's sale to Mars, Incorporated for $120.00 per share, TESSCO Technologies' sale to affiliates of Lee Equity Partners and Twin Point Capital for $9.00 per share, National Instruments' sale to Emerson Electric Co. for $60.00 per share, and Satsuma Pharmaceuticals' sale to Shin Nippon Biomedical Laboratories for $0.91 per share plus contingent value rights. The law firm stated it may seek increased consideration, additional disclosures, or other relief on behalf of shareholders.PR NewswireShareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin NipponAdemi LLP is investigating Satsuma Pharmaceuticals for possible breaches of fiduciary duty in its transaction with Shin Nippon. Shareholders are expected to receive $0.91 per share in cash plus a non-tradeable CVR worth up to $5.77 per share, with the CVR based on cumulative proceeds from Shin Nippon. The investigation also examines whether the board obtained a fair price and whether the agreement unreasonably limits competing bids.BenzingaWhy Marpai Shares Are Trading Lower By 26%; Here Are 20 Stocks Moving Premarket - Bionano Genomics (NASDAThis article provides a pre-market stock market update listing significant price movements for various publicly traded companies, including gains from acquisition announcements and losses due to bankruptcy filings or capital raises. Key events include Merck's agreement to acquire Prometheus Biosciences for $10.8 billion and Shin Nippon Biomedical Laboratories' plan to buy Satsuma Pharmaceuticals. Other notable movements involve Marpai dropping after a proposed public offering and Pear Therapeutics falling after filing for Chapter 11 bankruptcy.BioSpaceSatsuma Pharmaceuticals Provides STS101 Development Program and Corporate UpdateSatsuma Pharmaceuticals provided an update on its STS101 migraine treatment program, citing Phase 3 trial results showing robust and sustained antimigraine effects. The company plans to file an NDA in Q1 2023 and is seeking a commercialization partner.BenzingaDespite Trial Failure, Satsuma Pharma Says Its Migraine Candidate Has Potential For ApprovalSatsuma Pharmaceuticals announced that its SUMMIT Phase 3 efficacy trial of STS101 for acute migraine treatment did not achieve statistical significance versus placebo on the primary endpoint, though secondary endpoints showed differentiating and sustained effects. The company believes regulatory precedents support including portions of the trial data in the prescribing information and plans to submit an NDA to the FDA in Q1 2023 while simultaneously working to secure a commercialization partner for STS101.BenzingaWhy Satsuma Pharma (STSA) Shares Are Plunging TodaySatsuma Pharmaceuticals reported topline results from its STS101 SUMMIT Phase 3 efficacy trial for migraine patients, where the co-primary endpoints of pain freedom and freedom from most bothersome symptom at two hours post-dose did not achieve statistical significance. The company announced it will not pursue commercialization of STS101 and will actively explore alternatives, while shares plunged 82.2% to $0.72 in premarket trading.